Genzyme Reports Interim Data From Troubled Campath Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Multiple sclerosis therapy meets efficacy endpoints, but safety issues remain.
You may also be interested in...
CDER Taps Genzyme Exec As Deputy Director For Science Operations
Richard Moscicki will fill new position that will help oversee center operations and provide “executive direction,” joining fellow deputy directors Robert Temple and Douglas Throckmorton.
Genzyme Plans Campath MS Launch In 2009
Alemtuzumab Phase III trials in patients with multiple sclerosis are expected to begin next year.
Genzyme Plans Campath MS Launch In 2009
Alemtuzumab Phase III trials in patients with multiple sclerosis are expected to begin next year.